In-Bore Magnetic Resonance Imaging-Targeted Prostate Biopsy

Abstract

Over the last decade, multiparametric magnetic resonance imaging (mpMRI) of the prostate has evolved to be the preferred imaging modality for detecting and staging prostate cancer (PCa). Compared to transrectal ultrasound (TRUS)-guided systematic prostate biopsy (sPBx), MRI-guided prostate biopsy is more likely to detect clinically significant cancer with fewer cores. Gleason score obtained by MRI-guided biopsy also correlates better with the Gleason score of radical prostatectomy (RP) specimens. The precise identification of tumor location and aggressiveness allows for more confident selection of patients for active surveillance and focal ablation therapy. More accurate grading and staging of the tumor reduces the risk of inaccurate risk stratification and upgrading or upstaging the final diagnosis.